How to buy shares in MindMed
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MMEDF – and research it before deciding if it's a good...
Full Answer
How much does Mind Medicine (mindmed) stock cost?
One share of MMEDF stock can currently be purchased for approximately $1.25. How many employees does Mind Medicine (MindMed) have? Mind Medicine (MindMed) employs 22 workers across the globe.
What are the signals in the Mind Medicine stock?
There are mixed signals in the stock today. The Mind Medicine (MindMed) Inc. Subordinatestock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Can you buy or sell Mind Medicine?
You can buy or sell Mind Medicine and other ETFs, options, and stocks. Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine.
Should you invest in mindmed right now?
If you invested early in MindMed, you must be feeling pretty good about that decision right now. But the truth is that things are just getting started in the sector. Consumers want alternatives to traditional pharmaceuticals, particularly in the realm of mental health.
How can I buy mind medicine stock?
On the US OTC market, MindMed trades under the MMEDF ticker. You can see from the summary table above that both TD Ameritrade and E-Trade allow you to purchase shroom stocks from the United States. In addition, other brokers such as Charles Schwab and Fidelity offer trading of these stocks, often commission-free.
Is MindMed a good stock to buy?
Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is Mind Medicine publicly traded?
Trading is expected to begin on Tuesday, April 27, 2021, under the symbol “MNMD” on the Nasdaq. MindMed will retain its listing on the Neo Exchange Inc. under the symbol “MMED” and the Company's subordinate voting shares will continue to trade on the OTCQB under the symbol “MMEDF” until trading on the Nasdaq commences.
Will MindMed stock go up?
On average, analysts give MNMD a Strong Buy rating. The average price target is $8, which means analysts expect the stock to gain by 633.94% over the next twelve months. That average ranking earns MNMD an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.
How high will mind medicine stock go?
Stock Price Forecast The 5 analysts offering 12-month price forecasts for Mind Medicine (MindMed) Inc have a median target of 5.14, with a high estimate of 10.00 and a low estimate of 3.00.
What happened MindMed stock?
MindMed shares were trading around $5 in early 2021 after the company was officially registered on the NASDAQ. Since then, the stock has been gradually falling, losing 67% of its value in the past year.
Is MindMed on Nasdaq?
Stock Quote (U.S.: Nasdaq) | MarketWatch....$ 0.9300.CloseChgChg %$0.9087-0.0038-0.42%
Is MindMed trading on the Nasdaq?
Psychedelic drug development startup MindMed became the second company of its kind to list on the Nasdaq on Tuesday, but its share price crashed 30% during the first day of trading.
Is MindMed an IPO?
Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers. Psychedelics biotech platform Atai life Sciences has announced an initial public offering of approximately 14 million of its common shares, ahead of the company's expected Nasdaq listing.
Who are Mind Medicine (MindMed)'s key executives?
Mind Medicine (MindMed)'s management team includes the following people: Mr. Jamon Alexander Rahn , Co-Founder, CEO & Director Dr. Miriam Halperi...
Who are some of Mind Medicine (MindMed)'s key competitors?
Some companies that are related to Mind Medicine (MindMed) include 3SBio (TRSBF) , 45525 (CUR.TO) (CUR) , Abattis Bioceuticals (ATTBF) , Abcam...
What is Mind Medicine (MindMed)'s stock symbol?
Mind Medicine (MindMed) trades on the OTCMKTS under the ticker symbol "MMEDF."
How do I buy shares of Mind Medicine (MindMed)?
Shares of MMEDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Mind Medicine (MindMed)'s stock price today?
One share of MMEDF stock can currently be purchased for approximately $0.77.
How many employees does Mind Medicine (MindMed) have?
Mind Medicine (MindMed) employs 22 workers across the globe.
What is Mind Medicine (MindMed)'s official website?
The official website for Mind Medicine (MindMed) is www.mindmed.co .
Is Mind Medicine (MindMed) a buy right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last twelve months. There are currently 3 b...
How were Mind Medicine (MindMed)'s earnings last quarter?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) released its earnings results on Monday, March, 28th. The company reported ($0.04) earnings per share (E...
What price target have analysts set for MNMD?
3 brokerages have issued 1-year price targets for Mind Medicine (MindMed)'s shares. Their forecasts range from 6.00 to 10.00. On average, they expe...
Who are Mind Medicine (MindMed)'s key executives?
Mind Medicine (MindMed)'s management team includes the following people: Mr. Robert Barrow , CEO & Director (Age 33, Pay $708.41k) Dr. Miriam Ha...
Who are some of Mind Medicine (MindMed)'s key competitors?
Some companies that are related to Mind Medicine (MindMed) include Cronos Group (CRON) , Cresco Labs (CRLBF) , Sundial Growers (SNDL) , Aurora...
What is Mind Medicine (MindMed)'s stock symbol?
Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol "MNMD."
Who are Mind Medicine (MindMed)'s major shareholders?
Mind Medicine (MindMed)'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (...
Which major investors are selling Mind Medicine (MindMed) stock?
MNMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Simplex Trading LLC...
Which major investors are buying Mind Medicine (MindMed) stock?
MNMD stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, MMCAP International Inc. SPC, Pen...
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
MindMed share dividends
We're not expecting MindMed to pay a dividend over the next 12 months.
Have MindMed's shares ever split?
MindMed's shares were split on a 1:8 basis on 3 March 2020. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MindMed shares – just the quantity.
MindMed overview
Mind Medicine (MindMed) Inc. , a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.
MindMed in the news
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.
Headlines
UPDATE: Maxim Group On Mind Medicine: Firm Believes Co. Has 'One Of The Most Diverse Pipelines In Psychedelics' With $160M In Cash.
Mind Medicine (MindMed) (OTCMKTS:MMEDF) Frequently Asked Questions
Mind Medicine (MindMed)'s stock was trading at $0.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MMEDF shares have increased by 245.7% and is now trading at $1.21. View which stocks have been most impacted by COVID-19.
About Mind Medicine (MindMed)
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M.
3.5 Analyst's Opinion
Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Is Mind Medicine (MindMed) a buy right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last year. There are currently 2 buy ratings for the stock.
Are investors shorting Mind Medicine (MindMed)?
Mind Medicine (MindMed) saw a increase in short interest in January. As of January 31st, there was short interest totaling 23,480,000 shares, an increase of 30.1% from the January 15th total of 18,050,000 shares. Based on an average daily trading volume, of 5,150,000 shares, the days-to-cover ratio is currently 4.6 days.
When is Mind Medicine (MindMed)'s next earnings date?
Mind Medicine (MindMed) is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022. View our earnings forecast for Mind Medicine (MindMed).
What price target have analysts set for MNMD?
2 equities research analysts have issued 12 month price targets for Mind Medicine (MindMed)'s shares. Their forecasts range from 6.00 to 10.00. On average, they expect Mind Medicine (MindMed)'s share price to reach 8.00 in the next year.
Who are some of Mind Medicine (MindMed)'s key competitors?
Some companies that are related to Mind Medicine (MindMed) include Valneva (VALN), Nektar Therapeutics (NKTR), Fulgent Genetics (FLGT), Olink Holding AB (publ) (OLK), Taro Pharmaceutical Industries (TARO), Exscientia (EXAI), Ironwood Pharmaceuticals (IRWD), Schrödinger (SDGR), Cytek BioSciences (CTKB), 1Life Healthcare (ONEM), Mawson Infrastructure Group (WIZP), Definitive Healthcare (DH), USANA Health Sciences (USNA), Recursion Pharmaceuticals (RXRX) and Veracyte (VCYT). View all of MNMD's competitors..
Mind Medicine MindMed
Some stock charts might currently not be supported. To try again, please refresh this page.
About MNMD
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M.
What is MindMed?
MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company , announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license. MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.
What is MindMed's IND?
MindMed is on target to formally submit its Investigational New Drug (IND) application for Project Lucy in Q3 2021 and expects to launch its Phase 2b clinical trial shortly thereafter in Q4 2021.
Where is MindMed conducted?
The study will be conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland , and is planned to start this month.
Signals & Forecast
The Mind Medicine (MindMed) Inc. Subordinate stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Support, Risk & Stop-loss
Mind Medicine (MindMed) Inc. Subordinate finds support from accumulated volume at $1.17 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Mind Medicine (MindMed) Inc. Subordinate Voting Shares stock A Buy?
Mind Medicine (MindMed) Inc. Subordinate holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Insiders are very negative selling more shares than they are buying in Mind Medicine (MindMed) Inc. Subordinate
In the last 2 trades there were 209.02 thousand shares sold. The last trade was done 8 days ago by Barrow Robert who sold 18.73 thousand shares. In general the insiders are selling more stocks than they buy. There can be a variety of reasons for this, but in general it can be considered as a negative signal.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Who is the CEO of MindMed?
MindMed CEO JR Rahn and Director Stephen Hurst with venture capitalist Kevin O'Leary. Even psychedelic companies require a board. Co-founders JR Rahn and Stephen Hurst are readjusting their roles, with Rahn to become the only CEO on the board and Hurst to be a director. Formerly, Hurst was co-CEO along with Rahn.
Is Compass Pathways a mental health company?
Investors are comparing it to Compass Pathways (NASDAQ:CMPS), another mental health company that has been treating patients with psychedelics. Compass, traded on a U.S. exchange, has skyrocketed by 430.82 percent since it went public in Sept. 2020.
Is MindMed legal in the US?
Psychedelic legalization in the U.S. is a slow process, and that's why U.S.-based MindMed has to trade on international exchanges. This is despite the fact that foreign psychedelic companies can trade domestically based on the home country's legal status, as seen with U.K.-based Compass.
Is MindMed a valid influencer?
WallStreetBets' 10 million readers makes its a valid influencer in the market. The subreddit community has been discussing MindMed stock, focusing both on its MMED ticker on the NEO Exchange and its MMEDF ticker on OTC (over-the-counter) markets. Investors are comparing it to Compass Pathways (NASDAQ:CMPS), another mental health company that has been treating patients with psychedelics.
